Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint

  title={Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint},
  author={Elisabeth Mahase},
Production of dexamethasone must be rapidly ramped up to meet global demand for the drug, the World Health Organization has said.1 The call came as the University of Oxford’s RECOVERY trial published its much anticipated preprint paper2 on the drug’s effect on covid-19. The paper states that the drug cuts deaths in ventilated patients by one third and deaths in other admitted patients receiving oxygen by only one fifth. The headline findings of the trial were reported by the investigators on… Expand

Topics from this paper

COVID-19, corticosteroids and public health: a reappraisal
Whether the use of dexamethasone, beyond regulatory indications, may be responsible for the recent increase in mortality is investigated. Expand
COVID19: Dexamethasone; death or deliverer therefrom?
The benefits of the use of dexamethasone are undeniable and therefore the drug should be implemented into the treatment regime with a guarded approach. Expand
Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019
Evidence from a randomized control study found dexamethasone is effective in decreasing mortality in severe CO VID-19 cases and more studies are needed to validate the benefit of corticosteroids in COVID-19. Expand
ECCO2R with cytokine filtering in COVID-19 patients: Who wants to go down this road?
The experience with the most serious complications of COVID-19 seems to confirm the feasibility and usefulness of the combined treatment with Tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, as previously described for the treatment of CRS, and the use of CytoSorb during non-invasive ventilation in series with the ECCO2R device system. Expand
Editorial: intended victim or innocent bystander? The liver in COVID‐19
It is reconfirmed that COVID-19 is more likely to be severe and fatal in older and male patients and showed associations between white cell abnormalities (relative lymphopenia and relative neutrophilia) and adverse outcomes. Expand
Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic
This review summarizes the preliminary opinion about the dexamethasone outbreak, therapeutic potential, risks, and strategies during the COVID-19 pandemic. Expand
Primed for global coronavirus pandemic: Emerging research and clinical outcome
The global effort to combat and contain the coronavirus disease 2019 (COVID-19) pandemic is now proceeding on a war footing. The world was slow to react to the developing crisis, but once theExpand
A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes
A simple treatment paradigm using two generic drugs targeting the hyperinflammatory response that characterizes the turning point from mild to severe/critical COVID-19 by targeting leukotriene biosynthesis with zileuton and antagonism of the cysteinyl leukOTriene 1 receptor with montelukast (Singulair®). Expand
Identification and Development of Therapeutics for COVID-19
How different modes of identifying candidate therapeutics have borne out during the COVID-19 pandemic is explored, providing important insight into how the ongoing pandemic can be managed and also demonstrates the power of interdisciplinary collaboration to rapidly understand a virus and match its characteristics with existing or novel pharmaceuticals. Expand
Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?
The concomitant use of dexamethasone and one of the tetracyclines among severe COVID-19 patients offers several advantages in terms of additive immunomodulatory effects, cost-effectiveness, wide-availability, and well-known pharmacological properties including adverse-effect profile and contraindications. Expand


Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds
Low dose dexamethasone reduces deaths in patients hospitalised with covid-19 who need ventilation, according to preliminary results from the RECOVERY trial. The drug was also found to reduce deathsExpand